Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS). [electronic resource]
Producer: 20101020Description: 4299-308 p. digitalISSN:- 0008-543X
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Female
- Humans
- Lymphoma, Follicular -- drug therapy
- Male
- Middle Aged
- Mitoxantrone -- administration & dosage
- Neoplasms, Second Primary -- epidemiology
- Recurrence
- Rituximab
- Tumor Burden
- Vidarabine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.